In this large, real-world retrospective cohort study utilizing data from the TriNetX global health research network, we demonstrate that treatment with GLP-1 receptor agonists and dual GLP/GIP receptor agonists is associated with a significantly reduced risk of biliary complications among patients with coexisting type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD). Here, GLP1R is linked to type 2 diabetes mellitus.